High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes

Prescreening of participants in clinical trials that use adeno-associated virus (AAV) vectors is required to identify naive participants, as preexisting neutralizing antibodies can limit the efficacy of AAV gene therapies. The presence of antibodies to individual AAV serotypes is typically detected...

Descripción completa

Detalles Bibliográficos
Autores principales: Gardner, Matthew R., Mendes, Desiree E., Muniz, Claudia P., Martinez-Navio, José M., Fuchs, Sebastian P., Gao, Guangping, Desrosiers, Ronald C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800062/
https://www.ncbi.nlm.nih.gov/pubmed/35141348
http://dx.doi.org/10.1016/j.omtm.2022.01.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800062/
https://www.ncbi.nlm.nih.gov/pubmed/35141348
http://dx.doi.org/10.1016/j.omtm.2022.01.003

Ejemplares similares